glp-1 alcohol Anti-Obesity Rx and and Substance Use Disorders GLP‐1 Receptor Agonists for Treating

A poll released Friday by KFF found that about 1 in 8 adults say they are currently taking a GLP-1 drug to treat a chronic disease, for weight loss or both an increase of 6% since May 2024

Tirzepatide (weekly injectable) Dosing frequency: Once weekly, same day each week Half-life: approximately 5 days (120 hours) Peak concentration: 8 to 72 hours after injection Recommended timing approach: The shorter half-life compared to semaglutide means the end-of-week trough is more noticeable

Boster advised working with your healthcare team to add healthy habits to your overall lifestyle, whether you take GLP-1 agonists or not

Long-term inflammation is linked to: Type 2 diabetes Heart disease Fatty liver (NAFLD/NASH) Obesity Autoimmune and gut disorders Experts believe metabolic inflammation is a root cause of insulin resistance and poor cardiovascular outcomes

That comparison can be misleading because these are fundamentally different product categories